晶华微(688130) - 晶华微投资者关系活动记录表（20240709）

Financial Performance - The company achieved operating revenue of 26.70 million yuan, a year-on-year decrease of 8.81% [2] - The decline in revenue is attributed to intensified competition and seasonal factors [2] Product Development - The company focuses on the R&D and sales of high-performance analog and mixed-signal integrated circuits, including medical health SoC chips and industrial control chips [2] - In 2024, the company aims to enhance domestic substitution and will focus on developing battery management chip product series [2] - Key products to be launched include blood glucose meter chips with HCT functionality and multi-cell lithium battery charge and discharge management analog front-end BMS chips [2] Market Strategy - The company is conducting in-depth research and analysis for battery management chips tailored to various application scenarios and markets [3] - The company has accumulated expertise in high-precision ADC core technology and has a seasoned team to support product development [3] - The goal is to cover a larger market scale with the upcoming product series [3]